An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease

British Journal of Clinical Pharmacology

Volumn 62, Issue 2, 2006, Pages 138-152

  Giembycz, Mark A ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Cilomilast; COPD; Inflammation; PDE4 inhibitors

Indexed keywords

3',5'-CYCLIC-AMP PHOSPHODIESTERASES; 3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ADULT; AGED; AGED, 80 AND OVER; CARBOXYLIC ACIDS; CLINICAL TRIALS, PHASE III; CLINICAL TRIALS, PHASE III AS TOPIC; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; CYCLOHEXANECARBOXYLIC ACIDS; FEMALE; HUMANS; MALE; MIDDLE AGED; NITRILES; PHOSPHODIESTERASE INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESEARCH DESIGN; RESPIRATORY FUNCTION TESTS; TREATMENT OUTCOME;

EID: 33748267734     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2006.02640.x     Document Type: Review

References (67)

1. Briggs DD. Chronic obstructive pulmonary disease overview: prevalence, pathogenesis, and treatment. J Manag Care Pharm 2004; 10: S3-10.
2. Anto JM, Vermeire P, Vestbo J, Sunyer J. Epidemiology of chronic obstructive pulmonary disease. Eur Respir J 2001; 17: 982-94.
3. Almagro P, Calbo E, Ochoa dE, Barreiro B, Quintana S, Heredia JL, Garau J. Mortality after hospitalization for COPD. Chest 2002; 121: 1441-8.
4. Hurd S. The impact of COPD on lung health worldwide: epidemiology and incidence. Chest 2000; 117: 1S-4S.
5. Alsaeedi A, Sin DD, McAlister FA. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med 2002; 113: 59-65.
6. Barnes PJ. Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161: 342-4.
7. Torphy TJ. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 1998; 157: 351-70.
8. Giembycz MA. Development status of second generation PDE4 inhibitors for asthma and COPD: the story so far. Monaldi Arch Chest Dis 2002; 57: 48-64.
9. Giembycz MA. Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here? Drugs 2000; 59: 193-212.
10. Dyke HJ, Montana JG. Update on the therapeutic potential of PDE4 inhibitors. Expert Opin Invest Drugs 2002; 11: 1-13.
11. Torphy TJ, Barnette MS, Underwood DC, Griswold DE, Christensen SB, Murdoch RD, Nieman RB, Compton CH. Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic. Pulm Pharmacol Ther 1999; 12: 131-5.
12. Giembycz MA. Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease. Expert Opin Invest Drugs 2001; 10: 1361-79.
13. Souness JE, Rao S. Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases. Cell Signal 1997; 9: 227-36.
14. GlaxoSmithKline. SB 207499 (Ariflo, Cilomilast). New Drugs Application (21-573). Pulmonary and Allergy Drug Products Advisory Committee. Discussion of Benefit/Risk 2003. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3976B1-01_I- Glaxo-Benefit-Risk.pdf (last accessed: 9 February 2006).
15. GlaxoSmithKline. SB 207499 (Ariflo, Cilomilast). New Drugs Application (21-573). Pulmonary and Allergy Drug Products Advisory Committee Briefing Document 2003. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3976B1-02_D-FDA- %20Tab%203.pdf (last accessed: 9 February 2006).
16. GlaxoSmithKline. SB 207499 (Ariflo, Cilomilast). New Drugs Application (21-573). Pulmonary and Allergy Drug Products Advisory Committee. Introduction and Background 2003. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3976B1- 01_B-Glaxo-Intro-Background.pdf (last accessed: 9 February 2006).
17. Bland JM, Altman DG. Some examples of regression towards the mean. BMJ 1994; 309: 780.
18. Bland JM, Altman DG. Regression towards the mean. BMJ 1994; 308: 1499.
19. GlaxoSmithKline. SB 207499 (Ariflo, Cilomilast). New Drugs Application (21-573). Pulmonary and Allergy Drug Products Advisory Committee. Pivotal Studies 2003. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3976B1-01_G-Glaxo- Pivotal%20Studies.pdf (last accessed: 9 February 2006).
20. Calverley PM, Burge PS, Spencer S, Anderson JA, Jones PW. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 2003; 58: 659-64.
21. Compton CH, Gubb J, Nieman R, Edelson J, Amit O, Bakst A, Ayres JG, Creemers JP, Schultze-Werninghaus G, Brambilla C, Barnes NC. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet 2001; 358: 265-70.
22. Zussman BD, Davie CC, Kelly J, Murdoch RD, Clark DJ, Schofield JP, Walls C, Birrell C, Webber D, Quinlan J, Ritchie SY, Carr A. Bioavailability of the oral selective phosphodiesterase 4 inhibitor cilomilast. Pharmacotherapy 2001; 21: 653-60.
23. Zussman BD, Benincosa LJ, Webber DM, Clark DJ, Cowley H, Kelly J, Murdoch RD, Upward J, Wyld P, Port A, Fuder H. An overview of the pharmacokinetics of cilomilast (Ariflo), a new, orally active phosphodiesterase 4 inhibitor, in healthy young and elderly volunteers. J Clin Pharmacol 2001; 41: 950-8.
24. Murdoch RD, Zussman B, Schofield JP, Webber DM. Lack of pharmacokinetic interactions between cilomilast and theophylline or smoking in healthy volunteers. J Clin Pharmacol 2004; 44: 1046-53.
25. Murdoch RD, Cowley H, Kelly J, Higgins R, Webber D. Cilomilast (Ariflo) does not potentiate the cardiovascular effects of inhaled salbutamol. Pulm Pharmacol Ther 2002; 15: 521-7.
26. Kelly J, Murdoch RD, Clark DJ, Webber DM, Fuder H. Warfarin pharmacodynamics unaffected by cilomilast. Ann Pharmacother 2001; 35: 1535-9.
27. GlaxoSmithKline. SB 207499 (Ariflo, Cilomilast). New Drugs Application (21-573). Pulmonary and Allergy Drug Products Advisory Committee. Summary of Clinical Pharmacology and Biopharmaceutics Findings 2003. http://www.fda.gov/ ohrms/dockets/ac/03/briefing/3976B1-02_E-FDA-Tab%204.pdf (last accessed: 9 February 2006).
28. GlaxoSmithKline. SB 207499 (Ariflo, Cilomilast). New Drugs Application (21-573). Pulmonary and Allergy Drug Products Advisory Committee. Overview of Clinical Development Program 2003. http://www.fda.gov/ohrms/dockets/ac/03/ briefing/3976B1-01_E-Glaxo-Overview%20Clinical%20Dev.pdf (last accessed: 9 February 2006).
29. Compton C, Gubb J, Cedar E, Bakst A, Neiman RB, Amit O, Ayers J, Brambilla C. Ariflo (SB 207499), a second generation, oral PDE4 inhibitor, improves quality of life in patients with COPD. Am J Respir Crit Care Med 1999; 159: A522.
30. GlaxoSmithKline. SB 207499 (Ariflo, Cilomilast). New Drugs Application (21-573). Pulmonary and Allergy Drug Products Advisory Committee. Clinical Pharmacology 2003. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3976B1-01_D- Glaxo-Clinical%20Pharmacology.pdf (last accessed: 9 February 2006).
31. GlaxoSmithKline. SB 207499 (Ariflo, Cilomilast). New Drugs Application (21-573). Pulmonary and Allergy Drug Products Advisory Committee. Study Design - Pivotal Studies 2003. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3976B1- 01_F-Glaxo-Study%20Design-Pivotal%20Studies.pdf (last accessed: 9 February 2006).
32. Edelson JD, Compton C, Nieman R, Robinson CB, Watt R, Amit O, Bagchi I, Rennard SI, Kelsen S, Strek M. Cilomilast (Ariflo), a potent, selective inhibitor of phosphodiesterase 4, improves lung function in patients with COPD: results of a 6-month trial. Am J Respir Crit Care Med 2001; 163: A277.
33. Ramsdell J, Edelson J, Compton C, Vleisides C, Amit O, Kelsen S, Strek M, Rennard SI, Chodosh S, Schachter N. Cilomilast, a potent, selective inhibitor of phosphodiesterase 4, improves small airway function in patients with chronic obstructive pulmonary disease. Eur Respir J 2001; 16: 94s.
34. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000; 117: 398S-401S.
35. Kelsen S, Rennard SI, Chodosh S, Schryver B, Vleisides C, Zhu J. COPD exacerbation in a 6-month traiul of cilomilast (Ariflo), a potent, selective phosphodiesterase 4 inhibitor. Am J Respir Crit Care Med 2002; 165: A271.
36. Chowdhury BA. Memorandum. Overview of the FDA Background Materials for NDA 21-573, Ariflo (Cilomilast) Tablets, 15 mg, for the Maintenance of Lung Function (FEV1) in Patients with Chronic Obstructive Lung Disease (COPD) 2003. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3976B1-02_B-FDA-Tab%201.pdf (last accessed: 9 February 2006).
37. Food and Drug Administration. Glaxo Ariflo Effect Size in COPD Questioned by FDA. 2003. http://www.fdaadvisorycommittee.com/FDC/AdvisoryCommittee/ Committees/Pulmonary-Allergy+Drugs/090503_Ariflo/090503_ArifloP.htm (last accessed: 9 February 2006).
38. Ram FS, Jardin JR, Atallah A, Castro AA, Mazzini R, Goldstein R, Lacasse Y, Cendon S. Efficacy of theophylline in people with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. Respir Med 2005; 99: 135-44.
39. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 145: 1321-7.
40. GlaxoSmithKline. SB 207499 (Ariflo, Cilomilast). New Drugs Application (21-573). Pulmonary and Allergy Drug Products Advisory Committee. Transcript of Hearing held on 5 September 2003 at the Holiday Inn Gaithersburg, Gaithersburg, Maryland, USA 2003. http://www.fda.gov/ohrms/dockets/ac/03/transcripts/3976T1. doc (last accessed: 9 February 2006).
41. van Grunsven PM, van Schayck CP, Derenne JP, Kerstjens HA, Renkema TE, Postma DS, Similowski T, Akkermans RP, Paskerde Jong PC, Dekhuijzen PN, van Herwaarden CL, van Weel C. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Thorax 1999; 54: 7-14.
42. 2 agonists for the management of stable chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis. Thorax 2003; 58: 580-4.
43. Gamble E, Grootendorst DC, Brightling CE, Troy S, Qiu Y, Zhu J, Parker D, Matin D, Majumdar S, Vignola AM, Kroegel C, Morell F, Hansel TT, Rennard SI, Compton C, Amit O, Tat T, Edelson J, Pavord ID, Rabe KF, Barnes NC, Jeffery PK. Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 168: 976-82.
44. Belman MJ, Botnick WC, Shin JW. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 153: 967-75.
45. GlaxoSmithKline. SB 207499 (Ariflo, Cilomilast). New Drugs Application (21-573). Pulmonary and Allergy Drug Products Advisory Committee. Supporting Studies 2003. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3976B1-01_H-Glaxo- Supporting%20Studies.pdf (last accessed: 9 February 2006).
46. O'Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 770-7.
47. Gibson GJ. Pulmonary hyperinflation a clinical overview. Eur Respir J 1996; 9: 2640-9.
48. Pellegrino R, Brusasco V. On the causes of lung hyperinflation during bronchoconstriction. Eur Respir J 1997; 10: 468-75.
49. Zamel N, McClean P, Zhu J, Schryver B, Madan A, Robinson CB, Faiferman I. Effect of cilomilast (Ariflo) on trapped gas volume and indices of hyperinflation in patients with chronic obstructive lung disease. Am J Respir Crit Care Med 2002; 165: A226.
50. Zhang J, Herman EH, Knapton A, Chadwick DP, Whitehurst VE, Koerner JE, Papoian T, Ferrans VJ, Sistare FD. SK & F 95654-induced acute cardiovascular toxicity in Sprague-Dawley rats - histopathologic, electron microscopic, and immunohistochemical studies. Toxicol Pathol 2002; 30: 28-40.
51. Hanton G, Le Net JL, Ruty B, Leblanc B. Characterization of the arteritis induced by infusion of rats with UK-61,260, an inodilator, for 24 h. A comparison with the arteritis induced by fenoldopam mesylate. Arch Toxicol 1995; 69: 698-704.
52. Larson JL, Pino MV, Geiger LE, Simeone CR. The toxicity of repeated exposures to rolipram, a type IV phosphodiesterase inhibitor, in rats. Pharmacol Toxicol 1996; 78: 44-9.
53. Robertson DG, Reily MD, Albassam M, Dethloff LA. Metabonomic assessment of vasculitis in rats. Cardiovasc Toxicol 2001; 1: 7-19.
54. Ruben Z, Deslex P, Nash G, Redmond NI, Poncet M, Dodd DC. Spontaneous disseminated panarteritis in laboratory beagle dogs in a toxicity study: a possible genetic predilection. Toxicol Pathol 1989; 17: 145-52.
55. Bishop SP. Animal models of vasculitis. Toxicol Pathol 1989; 17: 109-17.
56. GlaxoSmithKline. SB 207499 (Ariflo, Cilomilast). New Drugs Application (21-573). Pulmonary and Allergy Drug Products Advisory Committee. Nonclinical Findings 2003. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3976B1-01_C- Glaxo-Nonclinical%20Findings.pdf (last accessed: 9 February 2006).
57. Losco PE, Evans EW, Barat SA, Blackshear PE, Reyderman L, Fine JS, Bober LA, Anthes JC, Mirro EJ, Cuss FM. The toxicity of SCH 351591, a novel phosphodiesterase-4 inhibitor, in Cynomolgus monkeys. Toxicol Pathol 2004; 32: 295-308.
58. Data Monitor. Press Release. Merck Discontinues Development of PDE4 Inhibitor Compound. 2003. http://www.datamonitor.com/ ~90c3cffcaf0546f7ad089c97929631c8~/companies/company/?pid=E915DFB3-6FBF-4C67- AE8F-29EB1160FC4C&nid=816AB3F2-982C-44B3-887C-3451D89A6362&type= NewsWire&article=1 (last accessed: 9 February 2006).
59. Nyska A, Herbert RA, Chan PC, Haseman JK, Hailey JR. Theophylline-induced mesenteric periarteritis in F344/N rats. Arch Toxicol 1998; 72: 731-7.
60. Collins JJ, Elwell MR, Lamb JC, Manus AG, Heath JE, Makovec GT. Subchronic toxicity of orally administered (gavage and dosed-feed) theophylline in Fischer 344 rats and B6C3F1 mice. Fundam Appl Toxicol 1988; 11: 472-84.
61. GlaxoSmithKline. SB 207499 (Ariflo, Cilomilast). New Drugs Application (21-573). Pulmonary and Allergy Drug Products Advisory Committee. Preclinical Considerations 2003. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3976B1- 02_F-FDA-Tab%205.pdf (last accessed: 9 February 2006).
62. Food and Drug Administration. NDA 21-573, Ariflo (cilomilast) Tablets 15mg, by GlaxoSmithKline, for use in Chronic Obstructive Pulmonary Disease-Questions.http://www.fda.gov/ohrms/dockets/ac/03/questions/3976Q1_Draft. doc (last accessed: 9 February 2006).
63. Drug Development Technology. Ariflo (Cilomilast) - Oral PDE-IV Inhibitor for Chronic Obstructive Pulmonary Disease (COPD).http://www.drugdevelopment- technology.com/projects/ariflo/ (last accessed: 9 February 2006).
64. 2-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest 2002; 110: 1045-52.
65. Giembycz MA. 4D or not 4D - the emetogenic basis of PDE4 inhibitors uncovered? Trends Pharmacol Sci 2002; 23: 548.
66. GlaxoSmithKline. SB 207499 (Ariflo, Cilomilast). New Drugs Application (21-573). Pulmonary and Allergy Drug Products Advisory Committee. Prescribing Information 2003. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3976B1-02_G- FDA-Tab7-Part%201.pdf (last accessed: 9 February 2006).
67. Altana AG. Press Release. Altana Has Withdrawn the EU Marketing Authorisation Application for Daxas. 2005. http://www.altana.com/root/index.php? page_id=202&cms_press_id=377 (last accessed: 9 February 2006).